Understanding Long-Term Response Rates and Treatment Dilemmas in Diabetic Macular Edema
The live program has concluded.
If you attended, please click on the "Take Post-Test" button to claim your credit. If you did not attend, please stay tuned for the archived version, which will be available soon for on-demand viewing.
Overview
This continuing medical education (CME) activity captures content from a live symposium held on August 11, 2016, in San Francisco, California.Provided by Evolve Medical Education LLC and distributed with New Retina MD and Retina Today. Supported through an educational grant by Allergan plc. Learning Objectives
Upon completion of this activity, the participant should be able to:
- Recognize the importance of early diagnosis and treatment of diabetic macular edema
- Assess the response of anti-VEGF intravitreal injections for diabetic macular edema
- Discuss the current and potential future therapies to treat patients with diabetic macular edema who do not respond in a timely fashion to initial treatments
- Formulate strategies to best treat diabetic macular edema using a multimodal approach
Accreditation
ACCREDITATION STATEMENT Evolve Medical Education LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA CREDIT DESIGNATION STATEMENT Evolve Medical Education LLC designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Participation Method
To obtain AMA PRA Category 1 Credit™ for this activity, you must read the activity in its entirety and complete the Post Test/ Activity Evaluation Form, which consists of a series of multiple choice questions. To answer these questions online and receive real-time results, please visit evolvemeded.com and click “Online Courses.” Upon completing the activity and achieving a passing score of over 70% on the self-assessment test, you may print out a CME credit letter awarding 1 AMA PRA Category 1 Credit™ Alternatively, please complete the Post Test/Activity Evaluation Form and mail or fax to Evolve Medical Education LLC; PO Box 358; Pine Brook, NJ 07058; Fax: (610) 771-4443. The estimated time to complete this activity is 1 hour.
Faculty and Disclosures
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.Antonio Capone Jr, MD Associated Retinal Consultants Royal Oak, Michigan
David M. Brown, MD Retina Consultants of Houston Houston, Texas
Jorge A. Fortun, MD Bascom Palmer Eye Institute Miami, Florida
Adam T. Gerstenblith, MD Mid Atlantic Retina Specialists Hagerstown, Maryland
DISCLOSURE POLICY STATEMENT It is the policy of Evolve Medical Education LLC that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve Medical Education LLC has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.
The following faculty members have the following financial relationships with commercial interests:
Antonio Capone Jr, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Allergan. Grant/Research Support: Allergan.
David M. Brown, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Allergan; Bayer Corporation; Genentech; Novartis; Regeneron Pharmaceuticals; and Roche. Grant/Research Support: Allergan; Bayer Corporation; Genentech; Novartis; Regeneron Pharmaceuticals; and Roche.
Jorge A. Fortun, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Alcon; and ThromboGenics NV.
Adam T. Gerstenblith, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Allergan; and Regeneron Pharmaceuticals.
EDITORIAL SUPPORT DISCLOSURES Cheryl Cavanaugh, MS, director of operations, Evolve Medical Education LLC; and Michelle Dalton, medical writer; have no financial relationships with commercial interests. Rishi Singh, MD, peer reviewer, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Alcon; Genentech; Regeneron Pharmaceuticals; and ThromboGenics NV. Grant/Research Support: Alcon; Genentech; and Regeneron Pharmaceuticals.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve Medical Education LLC, New Retina MD, Retina Today, or Allergan.
OFF-LABEL STATEMENT This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
- CME/CE Broadcast Replay
Enhancing Collaborative Care in Retinal Diseases: A Focus on Injection Therapies
1.00 credit
Deepak Sambhara, MD
Katherine E. Talcott, MD
Roger A. Goldberg, MD, MBA
Christina Y. Weng, MD, MBA, FASRS
Katherine E. Talcott, MD
